Literature DB >> 16641448

Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.

M C Georges-Courbot1, H Contamin, C Faure, P Loth, S Baize, P Leyssen, J Neyts, V Deubel.   

Abstract

Clinical nonrandomized trials demonstrate some efficacy for ribavirin in the treatment of patients with severe Nipah virus-induced encephalitis. We report here that EICAR, the 5-ethynyl analogue of ribavirin, and the OMP-decarboxylase inhibitors 6-aza-uridine and pyrazofurin have strong antiviral activity against Nipah virus replication in vitro. Ribavirin and 6-aza-uridine were tested further in hamsters infected with a lethal dose of Nipah virus. The activity of these small-molecule inhibitors was compared with that of the interferon inducer poly(I)-poly(C(12)U). Both ribavirin and 6-aza-uridine were able to delay but not prevent Nipah virus-induced mortality. Poly(I)-poly(C(12)U), at 3 mg/kg of body weight daily from the day of infection to 10 days postinfection, prevented mortality in 5 of 6 infected animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641448      PMCID: PMC1472238          DOI: 10.1128/AAC.50.5.1768-1772.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation.

Authors:  Jason J Rodriguez; Jean-Patrick Parisien; Curt M Horvath
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Nipah virus: vaccination and passive protection studies in a hamster model.

Authors:  V Guillaume; H Contamin; P Loth; M-C Georges-Courbot; A Lefeuvre; P Marianneau; K B Chua; S K Lam; R Buckland; V Deubel; T F Wild
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

3.  Hendra virus V protein inhibits interferon signaling by preventing STAT1 and STAT2 nuclear accumulation.

Authors:  Jason J Rodriguez; Lin-Fa Wang; Curt M Horvath
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  A golden hamster model for human acute Nipah virus infection.

Authors:  K Thong Wong; Isabelle Grosjean; Christine Brisson; Barissa Blanquier; Michelle Fevre-Montange; Arlette Bernard; Philippe Loth; Marie-Claude Georges-Courbot; Michelle Chevallier; Hideo Akaoka; Philippe Marianneau; Sai Kit Lam; T Fabian Wild; Vincent Deubel
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

5.  STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.

Authors:  Christina M Ulane; Jason J Rodriguez; Jean-Patrick Parisien; Curt M Horvath
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice.

Authors:  Pieter Leyssen; Christian Drosten; Marcus Paning; Nathalie Charlier; Jan Paeshuyse; Erik De Clercq; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis.

Authors:  Elizaveta Padalko; Dieter Nuyens; Armando De Palma; Erik Verbeken; Joeri L Aerts; Erik De Clercq; Peter Carmeliet; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

8.  Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins.

Authors:  Man-Seong Park; Megan L Shaw; Jorge Muñoz-Jordan; Jerome F Cros; Takaaki Nakaya; Nicole Bouvier; Peter Palese; Adolfo García-Sastre; Christopher F Basler
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  STAT protein interference and suppression of cytokine signal transduction by measles virus V protein.

Authors:  Heidi Palosaari; Jean-Patrick Parisien; Jason J Rodriguez; Christina M Ulane; Curt M Horvath
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Nipah virus in Lyle's flying foxes, Cambodia.

Authors:  Jean-Marc Reynes; Dorian Counor; Sivuth Ong; Caroline Faure; Vansay Seng; Sophie Molia; Joe Walston; Marie Claude Georges-Courbot; Vincent Deubel; Jean-Louis Sarthou
Journal:  Emerg Infect Dis       Date:  2005-07       Impact factor: 6.883

View more
  44 in total

Review 1.  The immune response to Nipah virus infection.

Authors:  Joseph Prescott; Emmie de Wit; Heinz Feldmann; Vincent J Munster
Journal:  Arch Virol       Date:  2012-06-06       Impact factor: 2.574

2.  Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening.

Authors:  Michael K Lo; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2014-03-27       Impact factor: 5.970

3.  Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model.

Authors:  Justin G Julander; Venkatraman Siddharthan; Lawrence M Blatt; Kristiina Schafer; Robert W Sidwell; John D Morrey
Journal:  Virology       Date:  2006-11-21       Impact factor: 3.616

Review 4.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

Review 5.  Emerging paramyxoviruses: molecular mechanisms and antiviral strategies.

Authors:  Hector C Aguilar; Benhur Lee
Journal:  Expert Rev Mol Med       Date:  2011-02-24       Impact factor: 5.600

6.  Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action.

Authors:  Aparna Talekar; Antonello Pessi; Matteo Porotto
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

7.  CTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repair.

Authors:  Rui Tang; Xiao-Bing Cui; Jia-Ning Wang; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-09-05       Impact factor: 8.311

Review 8.  A treatment for and vaccine against the deadly Hendra and Nipah viruses.

Authors:  Christopher C Broder; Kai Xu; Dimitar B Nikolov; Zhongyu Zhu; Dimiter S Dimitrov; Deborah Middleton; Jackie Pallister; Thomas W Geisbert; Katharine N Bossart; Lin-Fa Wang
Journal:  Antiviral Res       Date:  2013-07-06       Impact factor: 5.970

9.  Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.

Authors:  Alexander N Freiberg; Melissa N Worthy; Benhur Lee; Michael R Holbrook
Journal:  J Gen Virol       Date:  2009-11-04       Impact factor: 3.891

10.  Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro.

Authors:  Mohamad Aljofan; Michael L Sganga; Michael K Lo; Christina L Rootes; Matteo Porotto; Adam G Meyer; Simon Saubern; Anne Moscona; Bruce A Mungall
Journal:  Virol J       Date:  2009-11-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.